Norbert Gattermann

Q: What Schools Are Affiliated With Norbert Gattermann

Norbert Gattermann is affiliated with the following schools: Heinrich Heine University Düsseldorf, University of Basel, University of Bologna

Norbert Gattermann's AcademicInfluence.com Rankings

Norbert Gattermann

Computer Science

#9914

World Rank

#10400

Historical Rank

Machine Learning

#4465

World Rank

#4515

Historical Rank

Artificial Intelligence

#4823

World Rank

#4886

Historical Rank

Database

#6869

World Rank

#7108

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Norbert Gattermann Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Norbert Gattermann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) (3337)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. (2009) (2236)
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. (2010) (878)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. (2007) (747)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013) (535)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. (2005) (377)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. (2011) (364)
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. (2000) (290)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. (2008) (288)
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias (2010) (283)
[Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction]. (2001) (271)
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. (1992) (268)
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. (2004) (258)
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study (2007) (256)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2019) (237)
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia (2006) (232)
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. (2010) (227)
Age‐related incidence and other epidemiological aspects of myelodysplastic syndromes (1992) (224)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study (2017) (212)
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study (2013) (211)
Intrakoronare, humane autologe Stammzelltransplantation zur Myokardregeneration nach Herzinfarkt (2001) (200)
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells (2013) (196)
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. (2007) (192)
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes (2011) (176)
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. (2010) (175)
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. (2011) (173)
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes (2012) (166)
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. (2006) (161)
Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. (1997) (159)
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia (2005) (158)
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) (2005) (156)
Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. (2002) (155)
Problems in the classification of CMML--dysplastic versus proliferative type. (1998) (155)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. (2016) (151)
Thalidomide for the treatment of patients with myelodysplastic syndromes (2002) (150)
Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase (2007) (145)
Chronically Ultraviolet‐exposed Human Skin Shows a Higher Mutation Frequency of Mitochondrial DNA as Compared to Unexposed Skin and the Hematopoietic System (1997) (141)
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C (2003) (130)
Risk Assessment in Chronic Myelomonocytic Leukemia (CMML) (2004) (127)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry (2016) (125)
No increase in age-specific incidence of myelodysplastic syndromes. (2004) (124)
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. (2009) (116)
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study (2018) (113)
From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. (2000) (113)
Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload (2008) (111)
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes (2007) (108)
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. (2012) (106)
Myelodysplastic syndromes in patients younger than age 50. (2006) (100)
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. (2009) (98)
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome (2009) (96)
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow (2006) (95)
The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence (2009) (93)
Iron overload in MDS—pathophysiology, diagnosis, and complications (2010) (91)
Two types of acquired idiopathic sideroblastic anaemia (AISA) (1990) (89)
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease (2007) (86)
Increasing incidence of myelodysplastic syndromes: real or fictitious? (1998) (81)
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis (2012) (80)
The JAK2 V617F mutation is rare in RARS but common in RARS-T (2006) (78)
Chronic myelomonocytic leukemia in the light of the WHO proposals. (2007) (77)
Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. (2012) (76)
Myelodysplastic syndromes. (2013) (75)
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. (2014) (74)
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload (2012) (70)
Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C (2010) (70)
Iron overload in myelodysplastic syndromes (MDS) (2017) (68)
Epidemiological and etiological aspects of myelodysplastic syndromes. (1995) (67)
Causes of death in 2877 patients with myelodysplastic syndromes (2016) (67)
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. (2005) (66)
New prognostic parameters for chronic myelomonocytic leukemia. (2002) (63)
Myelodysplastic syndromes: diagnosis, prognosis, and treatment. (2013) (63)
The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia , but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia (2005) (62)
High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. (2007) (62)
Two types of acquired idiopathic sideroblastic anaemia (AISA): a time‐tested distinction (2000) (60)
Distinct molecular phenotype of malignant CD34+ hematopoietic stem and progenitor cells in chronic myelogenous leukemia (2005) (60)
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature (2018) (59)
Valproic acid for the treatment of myeloid malignancies (2007) (59)
Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes (2009) (58)
The treatment of secondary hemochromatosis. (2009) (58)
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. (2008) (56)
Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. (1994) (55)
Severe Impairment of Nucleotide Synthesis Through Inhibition of Mitochondrial Respiration (2004) (54)
A heteroplasmic point mutation of mitochondrial tRNALeu(CUN) in non‐lymphoid haemopoietic cell lineages from a patient with acquired idiopathic sideroblastic anaemia (1996) (54)
All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. (1993) (54)
Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. (2007) (54)
Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes. (2009) (53)
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. (2010) (52)
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid (2011) (52)
Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes (2015) (50)
Angioimmunoblastic Lymphadenopathy (AILD) May Respond to Thalidomide Treatment: Two Case Reports (2002) (49)
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays (2008) (47)
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification (2007) (45)
Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study. (2008) (45)
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange (2012) (44)
New insights into transfusion-related iron toxicity: Implications for the oncologist. (2016) (44)
Favourable response to antithymocyte or antilymphocyte globulin in low‐risk myelodysplastic syndrome patients with a ‘non‐clonal’ pattern of X‐chromosome inactivation in bone marrow cells (2002) (42)
Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. (2005) (42)
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. (2007) (41)
Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. (2003) (41)
Impact on survival of different treatments for myelodysplastic syndromes (MDS). (2009) (40)
Therapy-related myeloid neoplasms following treatment with radioiodine (2012) (39)
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. (2013) (39)
Detection of the ageing-associated 5-Kb common deletion of mitochondrial DNA in blood and bone marrow of hematologically normal adults. Absence of the deletion in clonal bone marrow disorders. (1995) (39)
Quantitative real‐time reverse‐transcription polymerase chain reaction for diagnosis of BCR‐ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation (2003) (38)
Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome (2013) (38)
Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance. (2007) (37)
X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. (2006) (36)
Age-related transcription levels of KU70, MGST1 and BIK in CD34+ hematopoietic stem and progenitor cells (2007) (35)
Mitochondria Harbouring Mutant mtDNA a Cuckoo in the Nest? (1999) (35)
The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) (2008) (34)
Is acquired idiopathic sideroblastic anemia (AISA) a disorder of mitochondrial DNA? (1993) (34)
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes? (2013) (34)
Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome. (2004) (34)
MtDNA mutations associated with sideroblastic anaemia cause a defect of mitochondrial cytochrome c oxidase. (1998) (34)
Thalidomide for the treatment of idiopathic myelofibrosis (2004) (34)
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia (2014) (33)
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. (2010) (32)
Fatal Bleeding Due to a Heparin-Like Anticoagulant in a 37-Year-Old Woman Suffering From Systemic Mastocytosis (2008) (32)
Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals (2006) (31)
Mitochondrial DNA mutations in the hematopoietic system (2004) (31)
Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study (2012) (31)
Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. (2011) (31)
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system (2014) (31)
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. (2008) (31)
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial (2021) (29)
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes (2015) (29)
A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload. (2004) (29)
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. (2002) (28)
Efficacy and Safety of Deferasirox (Exjade ® ) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial (2008) (27)
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) (2016) (27)
Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome (2009) (27)
Nilotinib ( formerly AMN 107 ) , a highly selective BCR-ABL tyrosine kinase inhibitor , is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia (2008) (27)
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP). (2006) (27)
New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. (2017) (26)
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. (2014) (26)
Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. (2009) (25)
Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy (2009) (25)
Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results (2008) (25)
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance (2013) (25)
Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. (2009) (25)
Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome (2003) (24)
The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany (2013) (24)
Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. (2013) (23)
Imatinib in breast milk (2009) (22)
Treatment of advanced myelodysplastic syndromes with recombinant interferon‐alpha2b (1991) (21)
Myelodysplastische Syndrome (MDS) (2012) (21)
The MERRF mutation of mitochondrial DNA in the bone marrow of a patient with acquired idiopathic sideroblastic anemia (1999) (20)
Vertebral fractures in multiple myeloma: first results of assessment of fracture risk using dynamic contrast-enhanced magnetic resonance imaging (2002) (19)
Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP). (2007) (19)
Matched-Pair Analysis of 186 MDS Patients Receiving Iron Chelation Therapy or Transfusion Therapy Only. (2009) (19)
Valproic Acid (VPA) Achieves High Response Rates in Patients with Low-Risk Myelodysplastic Syndromes. (2005) (18)
A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) (2007) (18)
Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis (2017) (18)
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib (2005) (18)
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients (2014) (18)
Long‐term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis (2000) (18)
Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients (2019) (18)
The Evaluation Of Iron Deficiency And Iron Overload. (2021) (18)
The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract (2011) (18)
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes (2019) (18)
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. (2001) (17)
Live Now ‐ Pay by Ageing: High Performance Mitochondrial Activity in Youth and its Age‐Related Side Effects (2003) (17)
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis (2017) (17)
Megakaryocytes: origin of bleeding and thrombotic disorders (1994) (16)
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia (2009) (16)
Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance. (2007) (16)
A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis. (2006) (16)
Optimized PCR fragments for heteroduplex analysis of the whole human mitochondrial genome with denaturing HPLC. (2006) (16)
Pathophysiological and clinical aspects of iron chelation therapy in MDS. (2012) (16)
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations. (2015) (16)
Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML. (2018) (15)
Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. (2019) (15)
Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. (2016) (15)
A retrospective study evaluating the impact of infectious complications during azacitidine treatment (2017) (15)
MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 × 109/l (2008) (15)
Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature (2003) (15)
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide. (2015) (14)
P-113 The efficacy and tolerabilityof ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload (2005) (14)
The role of low-dose chemotherapy in myelodysplastic syndromes. (1992) (14)
Novel therapies in low- and high-risk myelodysplastic syndrome (2019) (13)
Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia. (1997) (13)
Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomize (2014) (13)
Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine. (2007) (13)
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update (2008) (12)
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update (2008) (12)
Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study, (2011) (12)
No large deletions of mitochondrial DNA in acquired idiopathic sideroblastic anemia (AISA) (1992) (12)
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2020) (12)
Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. (2000) (12)
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine (2009) (11)
Dynamische kontrastverstärkte MRT zur Beurteilung der Knochenmarksmikrozirkulation bei malignen hämatologischen Erkrankungen vor und während einer Thalidomidtherapie (2002) (11)
Comparison of in vitro growth characteristics of blast cell progenitors (CFU-L) in patients with myelodysplastic syndromes and acute myeloid leukemia. (1992) (11)
Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy (2018) (10)
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study. (2016) (10)
Adverse Effects of Interferon Treatment (1997) (10)
Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data. (2009) (10)
Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes (2009) (10)
Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies. (2004) (9)
A pilot study of bendamustine in elderly patients with high-risk MDS and AML (2007) (9)
Clinical Spectrum of Primary Adrenal Lymphoma: Results of a Multicenter Cohort Study. (2020) (9)
Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria (2010) (8)
X chromosome inactivation ratios in female carriers of X-linked sideroblastic anemia. (2001) (8)
Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes (2009) (8)
Improvement of refractory sideroblastic anaemia with ubidecarenone (1994) (8)
Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR) (2008) (8)
Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes (2020) (8)
Impact on Iron Removal of Dose Reduction for Non-Progressive Serum Creatinine Increases during Treatment with the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670). (2006) (8)
5-Azacitidine in Combination with Donor Lymphocyte Infusions for the Treatment of Patients with MDS or AML Relapsing after Allogeneic Stem Cell Transplantation. (2006) (8)
Myelodysplastic Syndromes: Aspects of Current Medical Care and Economic Considerations in Germany (2008) (8)
Hemoglobinopathy York [β146 (HC3) His⇒Pro]: first report of a family history (2001) (7)
γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm (2016) (7)
P129 Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670) (2007) (7)
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes (2019) (7)
Safety of deferasirox (Exjade®) in myelodysplastic syndromes (MDS) and non-MDS patients with transfusional iron overload : a pooled analysis focusing on renal function (2009) (7)
Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Is Effective in Reducing Iron Overload in Patients with Advanced Fibrosis and Cirrhosis. (2005) (7)
[Dynamic MRI of the lumbar spine for the evaluation of microcirculation during anti-angiogenetic therapy in patients with myelodysplastic syndromes]. (2002) (7)
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis (2017) (7)
Serum deoxythymidine kinase in myelodysplastic syndromes (1994) (7)
Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) (2007) (7)
[Multimodal therapy in locally advanced gastric cancer]. (2011) (7)
Trimodal therapy in squamous cell carcinoma of the esophagus (2011) (7)
Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry (2021) (6)
How frequent is mutation in the mitochondrial cytochrome c oxidase gene in patients with myelodysplastic syndromes? (2002) (6)
Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS. (2006) (6)
Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia (2009) (6)
The ratio between CD4 + and CD8 + cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide (2005) (6)
Comprehensive Genomic Analysis Provides Further Evidence That Iron Overload Can Induce Genetic Instability in Myelodysplastic Syndromes (2015) (6)
Treatment of Poor Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia with a Combination of 5-Azacytidine and Valproic Acid (2008) (6)
Treatment of patients with high-risk myelodysplastic syndromes (2007) (6)
Diagnosis and Therapy of Myelodysplastic Syndromes in Germany: A Retrospective Multicenter Analysis (2012) (6)
A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells (2021) (6)
[Myelodysplastic syndromes. The epidemiological and etiological aspects]. (2008) (6)
[The leukostasis syndrome with a cerebral infarct in rapidly progressing chronic lymphatic leukemia]. (1991) (6)
A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP). (2006) (5)
Mitochondrial DNA amplification in AML: a hypothesis. (1997) (5)
Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: Results in 76 patients (1994) (5)
CIDP and isolated osteosclerotic myeloma (2004) (5)
Ermöglicht die dynamische kontrastverstärkte MRT die Detektion frakturgefährdeter Wirbelkörper beim Multiplen Myelom (2002) (5)
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians (2016) (5)
Comparison of In Vitro Growth Characteristics of Blast Cell Progenitors (CFU-L) in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia (1992) (5)
LEUKOSTASE-SYNDROM MIT HIRNINFARKT BEI RASCH PROGREDIENTER CHRONISCHER LYMPHATISCHER LEUKAMIE (2008) (5)
[Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy]. (2002) (5)
Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide. (2005) (5)
Incidence and Prevalence of Patients with Myelodysplastic Syndromes (MDS) in Düsseldorf 1996-2005. (2009) (4)
recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in adults (2013) (4)
[The leukostasis syndrome]. (1991) (4)
In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time (2015) (4)
Human bocavirus is not detectable in bone marrow from patients with myelodysplastic syndromes (2011) (4)
Multicenter case series of primary adrenal lymphoma (2016) (4)
[Treatment of myelodysplastic syndromes]. (1987) (4)
P140 Reduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade®) in ironoverloaded patients with myelodysplastic syndromes (MDS) (2009) (4)
A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission (2011) (4)
Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study (2013) (4)
Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results. (2018) (4)
139 Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome C oxidase in two patients with acquired idiopathic sideroblastic anaemia (1997) (4)
169 Aggressive chemotherapy in MDS: The Düsseldorf experience (1997) (4)
Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes. (2009) (4)
A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM). (2006) (4)
Refractory anemia with excess of blasts in transformation: a dying category? (2001) (4)
27 Assessing the guidelines on iron chelation in MDS – where are we? (2009) (3)
PF409 DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192-WK RESULTS (2019) (3)
The IPSS-R has prognostic impact in untreated patients with MDS del(5q). (2015) (3)
Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation? (2020) (3)
Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes (2013) (3)
Arrythmogenic Right Ventricular Dysplasia (2016) (3)
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center. (2021) (3)
Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study (2012) (3)
Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int‐1‐risk MDS patients: Results of the phase II KALLISTO trial (2018) (3)
Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS) (2022) (3)
Dependency of Survival on Additional Karyotype Anomalies and Bone Marrow Blast Count in Patients Suffering from Myelodysplastic Syndromes with 5q Deletion. (2007) (3)
Dynamische MRT der Lendenwirbelsäule zur Beurteilung der Mikrozirkulation unter anti-angiogenetischer Therapie bei Patienten mit Myelodysplastischen Syndromen (2002) (3)
Clinical Benefit‐Risk Profile of Lenalidomide in Patients With Lower‐risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial (2019) (3)
Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study. (2019) (3)
Prognostic Factors in Treatment-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemia (t-AML). (2007) (3)
combination with all-trans retinoic acid Treatment of myelodysplastic syndromes with valproic acid alone or in (2013) (3)
Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents - a Single Center Experience (2016) (3)
Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS). (2009) (3)
Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia. (2004) (2)
How to treat MDS without stem cell transplantation. (2010) (2)
C014 Influence of different treatment strategies on the prognosis of patients with myelodysplastic syndromes (MDS) (2007) (2)
Myelodysplastic syndromes (MDS) in regular care in Germany – the oldest patients come to the fore (2018) (2)
[Does dynamic contrast-enhanced MRI enable recognition of development of vertebral fractures in multiple myeloma?]. (2002) (2)
57 How to assess the medullary blast count in MDS? Pay attention to the proportion of erythroid cells! (2011) (2)
Characteristics of Disease Progression in 3213 Patients with Myelodysplastic Syndrome (2008) (2)
Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial. (2004) (2)
Deferasirox (Exjade®) Treatment of Chelation-Naive and Pre-Chelated MDS Patients with Transfusional Iron-Overload in the Medical Practice:Results From the Observational Studies Extend and Exjange. (2009) (2)
Improving the accuracy of prognostication in chronic myelomonocytic leukemia (2020) (2)
93 Analysis of treatment choices and outcome for MDS and AML patients 60 years and older from the university of Dusseldorf (2011) (2)
312 Restratification of IPSS risk groups according to the WPSS identifies patients with myelodysplastic syndromes (MDS) at higher risk (2011) (2)
Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study (2013) (2)
Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion Dependent Anemias (2010) (2)
The Role of Mitochondria in MDS (2008) (2)
Iron rusting in the mitochondria? (2016) (2)
SF3B1 and the riddle of the ring sideroblast. (2012) (2)
160 ANALYSIS OF POSSIBLE BIOMARKERS TO PREDICT RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE (2015) (2)
Serum Protein Profiling with Mass Spectrometry for the Diagnosis of Myelodysplastic Syndromes. (2004) (2)
Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine (2013) (2)
O-51 Chelation therapy inmyelodysplastic syndrome: Update from recent clinical trials with oral agents (2005) (2)
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? (2021) (2)
Gene Expression Profiling of Philadelphia Chromosome(Ph) Negative CD34+ Hematopoietic Stem and Progenitor Cells of Patients with Ph Positive CML in Complete Molecular Remission during Therapy with Imatinib. (2004) (2)
P141 Efficacy and safety of deferasirox (Exjade®) in chelation-naive and previously chelated patients with transfusion-dependent myelodysplastic syndromes (MDS) (2009) (2)
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study (2022) (2)
Secondary Primary Malignancies in Patients with Multiple Myeloma Treated with High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation, (2011) (2)
Myelodysplastische Syndrome (2006) (2)
Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364). (2012) (2)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (2)
Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study (2008) (2)
Risk of leukemic transformation in two types of acquired idiopathic sideroblastic anemia. (1990) (2)
EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) (2008) (2)
Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom (2020) (2)
Iron overload in MDS: clinical consequences and management strategies (2007) (1)
Increased Cytogenetic Testing and Prognostic Assessment Do Not Translate Into Higher Active Treatment of Elderly MDS Patients in Germany (2011) (1)
Transfused Myelodysplastic Syndromes (MDS) Patients Have Severe Iron Overload and Relevant Improvements in Iron Burden and Liver Function with Deferasirox Treatment: Results From a Pooled Analysis (2011) (1)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (1)
Impaired formation of neutrophil extracellular traps in patients with MDS (2021) (1)
325 Validation of the ‘Texas Score’ for the prognostication of patients with myelodysplastic syndromes (2011) (1)
Incidence, Treatment and Course Of Disease Of Patients With del5q Myelodysplastic Syndrome (MDS) In The “pre-lenalidomide” Era In Germany. Data From The German Outpatient MDS Registry (2013) (1)
[The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome]. (1996) (1)
Mutations of Mitochondrial DNA as an Early Event in the Pathogenesis of Myelodysplastic Syndromes (1998) (1)
Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts (2021) (1)
P112 Prognostic impact of bone marrow fibrosis in myelodysplastic syndromes (MDS) (2007) (1)
Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients (2010) (1)
Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk (2010) (1)
Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow – derived and circulating human CD 34 1 hematopoietic stem cells (2002) (1)
[Role of aggressive treatment strategies for myelodysplastic syndromes]. (1999) (1)
[Therapy of transfusion hemochromatosis]. (1997) (1)
153 Analysis of causes of death in 2297 patients with myelodysplastic syndromes. Data from the Dusseldorf MDS registry (2011) (1)
Treatment with Azacitidine: A Retrospective Study Evaluating the Real Life Clinical Course and Impact on Infectious Complications (2015) (1)
P-4 Prognostic impact of bone marrow cellularity in myelodysplastic syndromes on overall survival (2005) (1)
Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). (2007) (1)
1855P Logistic and documentary factors influencing reasonable tumorboard decisions (2021) (1)
Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML (2019) (1)
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) (1)
Increased serum ferritin and genetic instability in myelodysplastic syndromes (2017) (1)
Differences In Clinical Characteristics and Prognostic Features Between Patients with Myelodysplastic Syndromes (MDS) From Korea, Japan, and Germany (2010) (1)
103 Therapy-related myeloid neoplasms following treatment with radioiodine (2011) (1)
Gene expression proﬁling identiﬁes signiﬁcant differences between the molecular phenotypes of bone marrow–derived and circulating human CD34 1 hematopoietic stem cells (2002) (1)
Albinism with Hemorrhagic Diathesis and Pigmented Reticuloendothelial Cells (2009) (1)
Therapy-Related Myeloid Neoplasms Following Treatment for Multiple Myeloma : A Single-Center Analysis (2019) (1)
Anaesthesia in a patient with subarachanoidal haemorrhage and high oxygen affinity haemoglobinopathy (HB york): case report (2012) (1)
Effect of Deferasirox Combined with Erythropoietin Versus Erythropoietin Alone on Erythroid Response in Patients with Low- and Int-1-Risk Myelodysplastic Syndromes: Results of the Phase II Kallisto Trial (2017) (1)
Prognostic Factors for CMV Reactivation/Infection after Stem Cell Transplantation and Value of Oral Valganciclovir for Preemptive Therapy. (2005) (1)
Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis (2022) (1)
Treatment Outcome of Patients with Myelodysplastic Syndromes (MDS) in Regular Care: Incidence of IPSS Risk Groups and Different Therapies in the German Outpatient MDS Registry (2014) (1)
Mitochondrial hematology and oncology (2006) (1)
23 Heterogeneity of acquired idiopathic sideroblastic anemia (AISA): Results of a prospective follow-up study in 189 patients (1997) (1)
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (2022) (1)
Functional Inhibition of Mesenchymal Stem and Progenitor Cells (MSPC) Significantly Contributes to Hematopoietic Insufficiency with Acute Myeloid Leukemia (AML) (2014) (1)
Hematopoiesis in Chronic Phase CML emerges from Hematopoietic Stem Cells with a Transcriptional Phenotype Resembling Normal Myeloid Progenitor Cells. (2008) (1)
Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre (2019) (1)
Analysis of Mesenchymal Stromal Cells (MSC) and Their Interactions with CD34 Stem and Progenitor Cells in Patients with Myelodysplastic Syndromes (MDS) (2011) (1)
P-29 RA and RARS with thrombocytosis:Mixed myelodysplastic/myeloproliferative disorder? (2005) (1)
Neut-X can be successfully used as diagnostic and prognostic tool in MDS. (2019) (1)
Is the IPSS-R Useful for Patients with MDS Receiving Disease-Modifying Treatment? (2016) (1)
New Trends in Iron Chelation: Impacting Outcomes (2007) (1)
P-5 Presence of peripheral blasts in RAand RARS predicts an unfavourable outcome (2005) (1)
ENESTfreedom 144‐Week Update: Long‐Term Treatment‐Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML‐CP): CML‐188 (2018) (1)
Descriptive Epidemiology of Myelodysplastic Syndromes (1994) (1)
340 Improvement in haematologic parameters in patients with MDS treated with the iron chelator deferasirox (Exjade®): An EPIC study post-hoc analysis (2011) (1)
C012 Prevalence and prognostic significance of allelic imbalance by single nucleotide polymorphism analysis in low risk myelodysplastic syndromes (2007) (1)
P-112 Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS (2005) (1)
Mastering the multitude of monocytoses (2019) (1)
Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes (2021) (1)
Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis (2015) (1)
PROGNOSTISCHE BEDEUTUNG DER SERUM-THYMIDINKINASE BEIM MYELODYSPLASTISCHEN SYNDROM (2008) (1)
Eisenchelat-Therapie mit Deferasirox: Therapiebeginn und Dosisoptimierung (2012) (1)
No evidence of increasing incidence of MDS (2003) (1)
14 Problems in the classification of CMML. Dysplastic vs profliferative type (1997) (1)
Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome (2013) (0)
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo (2022) (0)
P-42 Immediate early response gene 1 (IEX-1) is decreased in CD34+ bone marrow cells from patients with myelodysplastic syndromes (2005) (0)
No improvement of refractory sideroblastic anaemia with ubidecarenone (1995) (0)
P-255 Inclusion criteria of clinical trials do not meet the real MDS population. A registry-based simulation (2013) (0)
O-9 Familial myelodysplastic syndromein 4 patients with normal karyotype (2005) (0)
Reply to Valproic Acid for the Treatment of Myeloid Malignancies (2008) (0)
C006 Detailed morphologic findings in 2773 patients with myelodysplastic syndromes (2009) (0)
Severe Anemia Is Associated with a Risk of Infection in Patients with Myelodysplastic Syndromes (2021) (0)
Hematological Characteristics of Patients with Myelodysplastic Syndromes in the Light of WHO 2008 Proposals. (2008) (0)
P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY (2022) (0)
Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (2017) (0)
P-049 Clinical and prognostic relationship of CMML to MDS and MPS (2013) (0)
Transfusion History, Iron Chelation Practices and Status of Iron Overload across Various Transfusion-Dependent Anemias: Data from the Large-Scale, Prospective, 1-Year EPIC Trial (2008) (0)
Iron-overload links to genetic instability in myelodysplastic syndromes (2016) (0)
Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment. (2023) (0)
Exisulind Selectively Induces Apoptosis Via C-Jun Kinase Activation in MDS and sAML/MDS. (2005) (0)
Treatment free remission in CML patients after first line nilotinib therapy (2016) (0)
Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts (2022) (0)
Effect of Lenalidomide Exposure on Response and Outcomes in Patients with Lower-Risk Non-Del(5Q) Myelodysplastic Syndromes (MDS) (2017) (0)
In Reply. (2022) (0)
The Treatment of Secondary Hemochromatosis: In reply (2009) (0)
117 A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) (2015) (0)
119 UPDATE ON THE MULTICENTER MDS BIOREGISTRY PROJECT OF THE “KREBSHILFE-VERBUNDFORSCHUNGSPROJEKT MDS” OF THE GERMAN MDS STUDY GROUP (2015) (0)
P-239 Telomere length of granulocytes significantly increases during the first six months of lenalidomide treatment in patients with isolated 5q- syndrome (2013) (0)
Safety and Efficacy of a Six Month Full Dose Lenalidomide Consolidation Treatment After First-Line High-Dose Therapy in Patients with Multiple Myeloma (2012) (0)
syndromes single-nucleotide polymorphism analysis in low-risk myelodysplastic Prevalence and prognostic significance of allelic imbalance by (2013) (0)
γ-Glutamyl-Transferase ist ein unabhängiger Biomarker für splanchnische Thrombosen bei Patienten mit myeloproliferativen Neoplasien (2016) (0)
Short communication Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia (2005) (0)
Results of a Multicenter Treatment Survey Yielding Insights Into Diagnosis and Management of MDS Patients In Daily Clinical Practice In Germany (2010) (0)
Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q). (2016) (0)
Prognostic Factors for Outcome of Patients Undergoing Allogeneic HSCT from Unrelated and Related Donors for AML and MDS: A Retrospective Analysis. (2005) (0)
Dichotomous Synexpression of Fanconi Anemia/BRCA1 Pathway Proteins in Myelodysplastic Syndromes (2017) (0)
Validation of a Novel Algorithm with a High Specificity in Ruling out MDS (2022) (0)
Erste DGHO-Frühjahrstagung in Berlin: Brückenschlag zwischen Versorgung, Wissenschaft und Politik (2008) (0)
Recurrent reversible nephrotic syndrome during therapy with recombinant interferon alpha. (1997) (0)
Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie (2022) (0)
O-69 Characteristics of therapy-relatedMDS in 133 patients (2005) (0)
leukemia or chronic lymphocytic leukemia leukemia and acute myeloid leukemia, but not in acute lymphoblastic The JAK2V617F activating mutation occurs in chronic myelomonocytic (2013) (0)
Myelodysplastische Syndrome: Diagnostik und Therapie (2020) (0)
Influence of Different Treatment Modalities On the Prognosis of Patients with High Risk MDS Aged Above 60 Years. A Matched-Pairs Analysis. (2009) (0)
ASD (2021) (0)
Refractory and relapsing Hodgkin's disease: Role of high-dose chemotherapy with bone marrow transplantation (1990) (0)
Varying Importance of Prognostic Factors in Subgroups of Myelodysplastic Syndromes Defined by Blast Count, Cytogenetic Risk Group, or WHO Classification. (2009) (0)
Clinical Outcome of 40 Patients with Higher-Risk Myelodysplastic Syndromes (MDS) after Treatment with Hypomethylating Agents: a Matched-Pairs Analysis (2008) (0)
Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones (2009) (0)
Age-Related Transcription Levels of KU70 and BIK in CD34+ Hematopoietic Stem and Progenitor Cells. (2005) (0)
Therapieansätze bei Patienten mit Hochrisiko-MDS* (2011) (0)
Effect of the Neddylation Inhibitor Pevonedistat on Normal Hematopoietic Stem Cell Subsets and Immune Cell Composition (2021) (0)
Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes (2023) (0)
Neues aus Wissenschaft und Lehre der Heinrich-Heine-Universität Düsseldorf 2010 (2010) (0)
Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation (2016) (0)
[Pericarditis, pleurisy, pulmonary coin lesions: extra-articular manifestations of rheumatoid arthritis?]. (1988) (0)
Impaired Formation of Neutrophil Extracellular Traps (NETs) in Patients with Myelodysplastic Syndrome (MDS) (2020) (0)
P-22 Evaluation of the WHO proposals for the diagnosis of CMML (2005) (0)
Abstract (1984) (0)
Prevalence and prognostic signiﬁcance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes (2007) (0)
[Iron replacement. Oral or parenteral?]. (1998) (0)
Epigenetische Therapie beim MDS (2012) (0)
Monitoring of Wilms’ Tumor 1 (WT1) Expression in Peripheral Blood (PB) of Patients with Myelodysplastic Syndromes (MDS) By a Standardized European Leukemia Net (ELN)-Certified Assay to Detect Minimal Residual Disease (MRD) and Guide Therapeutic Interventions Following Allogeneic Transplantation (2014) (0)
Hämophagozytische Lymphohistiozytose (HLH) beim metastasierten Mammakarzinom – ein Case Report (2022) (0)
Prognostic Impact of Iron Overload and Iron Chelation in Myelodysplastic Syndromes (2020) (0)
Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial (2021) (0)
10 Increasing incidence of MDS: Real or fictitious? (1997) (0)
O-20 Noninvasive detection ofmyelodysplastic syndromes using serum proteome profiling (2005) (0)
Adenomatous Polyposis, Familial (2009) (0)
Imatinib Induced Molecular Response in CD34+ Hematopoietic Stem and Progenitor Cells of Patients with Chronic Myeloid Leukemia Following the First Week of Therapy (2008) (0)
Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia. (2006) (0)
DESCRIPTIVE ANALYSES OF DEFERASIROX SAFETY AND EXPOSURE IN PATIENTS AGED > 65 VERSUS 18 TO <= 65 YEARS (2015) (0)
Treatment of patients with myelodysplastic syndromes (2014) (0)
P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA (2022) (0)
Gastrointestinal disturbances in iron-overloaded myelodysplastic syndromes patients receiving concomitant medications during deferasirox treatment (2013) (0)
Induction of Complete Remission with 5-Azacytidine in a Patient with Acute Myeloid Leukemia Refractory to Intensive Chemotherapy. (2005) (0)
347 Successful treatment of transfusional iron overload in MDS patients with deferasirox as indicated by Liver-MRI: A German, multi-center trial (2011) (0)
Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013 (2014) (0)
P075 JAK2 and MPL515 mutation analysis in RARS with platelets ≥500.000/μl and in RARS-T according to WHO (platelets ≥600.000/μl) (2007) (0)
P-6 Characteristics of myelodysplastic syndromes in patients under 50 years of age (2005) (0)
C024 Impaired mitochondrial gene expression in MDS patients (2007) (0)
Short title: Therapy-related MDS and AML after radioiodine treatment (2011) (0)
Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study (2019) (0)
Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI) (2022) (0)
and the riddle of the ring sideroblast (2012) (0)
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS (2022) (0)
Corrigendum to “When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?” [Best Pract Res Clin Haematol (2013) 431–444] (2014) (0)
Deferasirox - : nur einmal täglich oral (2006) (0)
119 2011-update and overview of data in the German-Austrian-Suisse MDS registry (D-A-CH MDS registry) (2011) (0)
Meetings and Conferences · Tagungen und Kongresse (2001) (0)
Influence of Haemodialysis on Imatinib Plasma Levels in a Case of Philadelphia Positive Acute Lymphoblastic Leukemia (2018) (0)
Protein expression and clinical significance of the NEDDylation pathway in myelodysplastic syndrome (2018) (0)
Pharmakologie und Pharmakotherapie (2000) (0)
Correspondence (1999) (0)
PO001 Smoking is not a risk factor for fungal pneumonia in MDS and AML patients undergoing chemotherapy (2007) (0)
P-107 Treatment of patients with high-risk MDS and sAML with Bendamustin (2005) (0)
Transcriptional Changes Induced by Imatinib and Nilotinib in the Chronic Myelogenous Leukemia (CML) Cell Line K562. (2007) (0)
PF311 ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY (2019) (0)
In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time (2014) (0)
295 Validation of the WHO 2008 classification for ‘non-blastic’ myelodysplastic syndromes. Lumping or splitting? (2011) (0)
Evolution of Cellular Haemostasis: The Stem Cell-Megakaryocyte-Blood Platelet System (1996) (0)
mutations in myeloid leukemia patients High-throughput sequencing screen reveals novel, transforming RAS (2013) (0)
56 Prognostic impact of cytogenetic investigations in 270 patients with primary myelodysplastic syndromes (1997) (0)
Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry (2014) (0)
Concordant Underexpression of Fanconi Anemia/BRCA1 Pathway Proteins in a Major Proportion of Myelodysplastic Syndromes (2016) (0)
307 A comparison of clinical characteristics and the role of prognostic markers in 1757 MDS patients from Japan, Korea, and Germany (2011) (0)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (0)
Antisense RNA crossing mitochondrial membrane (1998) (0)
Andersen disease (2019) (0)
55 Independent validation of the MDS Comorbidity Score (MDS-CI) (2011) (0)
acute lymphoblastic The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic (2005) (0)
The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis. (2004) (0)
304 Clinical impact of trisomy 11 in patients with MDS and AML (2011) (0)
Aortic Root to Right Heart Shunts (2009) (0)
WT1 mRNA Expression in the Peripheral Blood of Patients with MDS Yields Additional Prognostic Information within the IPSS-R Risk Categories "Very Low", "Low" and "Intermediate" (2018) (0)
P-67 Hyperdiploidy in MDS and AML is associated with poor prognosis (2005) (0)
Severe Cryoglobulinemic Vasculitis After Cytoreductive Therapy In Waldenström´S Macroglobulinemia And Hepatitis C-Virus: A Case Report (2022) (0)
Invited Lectures26 Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload (2007) (0)
C004 Relevance of prognostic factors in different subgroups of myelodysplastic syndromes (2009) (0)
C006 Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification (2007) (0)
Scharf " Evaluation of iron status in voluntary blood donors " (2017) (0)
nucleotide polymorphism analysis in low risk myelodysplastic syndromes Prevalence and prognostic significance of allelic imbalance by single (2013) (0)
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia (2014) (0)
Antisense RNA crossing mitochondrial membrane? (1998) (0)
P-30 Prospective validation of the WHO classification of primary myelodysplastic syndromes (2005) (0)
169 A multicenter analysis of MDS diagnosis and treatment in daily clinical practice in Germany (2011) (0)
[Diagnosis and therapy strategy in myelodysplastic syndromes]. (1996) (0)
Case of the month Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature (2000) (0)
P-093 Hypoplastic myelodysplastic syndromes are not a specific clinical entity (2013) (0)
A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Proﬁle: Final Results of the Valena Trial (2014) (0)
Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study (2013) (0)
P124 Matched pair analysis of conventional regimens versus hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes – an analysis from the Duesseldorf MDS Registry (2009) (0)
Sequential Induction Chemotherapy, and Early Intensified Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Myeloid Leukemia. (2006) (0)
Molecular Phenotype of Malignant CD34+ Hematopoietic Stem and Progenitor Cells in Chronic Myelogenous Leukemia. (2005) (0)
Comparison of Cytomorphology and Histopathology in Myelodysplastic Syndromes (MDS) (2022) (0)
The JAK2 V617F Mutation Identifies Specific Subgroups of Myelodysplastic Syndrome (MDS). (2006) (0)
An Analysis of Treatment Choices for Acute Myeloid Leukemia in Patients 60 Years and Older from the University of Duesseldorf AML/MDS Database. (2007) (0)
Acknowledgement to Referees (2005) (0)
P772: PROGNOSTIC IMPACT OF DISEASE-RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS) (2022) (0)
C007 Validation of the WHO proposals for the classification of unclassifiable myelodysplastic syndromes (2009) (0)
adults : recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in (2013) (0)
Disease Characteristics, Treatment and Outcome of Patients with Myelodysplastic Syndromes Relapsing after Allogeneic Stem Cell Transplantation (2015) (0)
P-28 Refractory anemia with excess of blasts (RAEB): Analysis of reclassification of the WHO (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Norbert Gattermann?

Norbert Gattermann is affiliated with the following schools:

Heinrich Heine University Düsseldorf
University of Basel
University of Bologna

Norbert Gattermann's Academic­Influence.com Rankings

Why Is Norbert Gattermann Influential?

Norbert Gattermann's Published Works

Published Works

What Schools Are Affiliated With Norbert Gattermann?

Norbert Gattermann's AcademicInfluence.com Rankings